Crescent Biopharma (NASDAQ:CBIO) CEO Joshua Brumm Sells 7,837 Shares of Stock

Crescent Biopharma, Inc. (NASDAQ:CBIO) CEO Joshua Brumm sold 7,837 shares of the business’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.71, for a total transaction of $130,956.27. Following the completion of the sale, the chief executive officer owned 271,765 shares in the company, valued at $4,541,193.15. This represents a 2.80% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Crescent Biopharma Stock Performance

CBIO opened at $16.89 on Friday. The firm has a market cap of $627.29 million, a price-to-earnings ratio of -2.51 and a beta of 1.24. The firm’s 50-day simple moving average is $17.12 and its 200-day simple moving average is $17.43. Crescent Biopharma, Inc. has a twelve month low of $8.72 and a twelve month high of $27.41.

Crescent Biopharma (NASDAQ:CBIO) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.74). As a group, sell-side analysts anticipate that Crescent Biopharma, Inc. will post -2.91 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on CBIO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Crescent Biopharma in a report on Friday, August 7th. TD Cowen raised Crescent Biopharma to a “strong-buy” rating in a research note on Monday, August 24th. Wedbush restated an “outperform” rating and set a $27.00 target price on shares of Crescent Biopharma in a report on Monday, September 14th. Finally, HC Wainwright restated a “neutral” rating on shares of Crescent Biopharma in a research note on Thursday, July 16th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.60.

Institutional Trading of Crescent Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of CBIO. Legal & General Group Plc acquired a new position in Crescent Biopharma during the 2nd quarter worth $38,000. Cannon Global Investment Management LLC acquired a new stake in shares of Crescent Biopharma in the 1st quarter valued at $187,000. Persistent Asset Partners Ltd acquired a new stake in shares of Crescent Biopharma in the 2nd quarter valued at $197,000. Wellington Management Group LLP bought a new stake in shares of Crescent Biopharma during the second quarter worth $263,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Crescent Biopharma during the second quarter worth $320,000. Institutional investors and hedge funds own 75.19% of the company’s stock.

Key Stories Impacting Crescent Biopharma

Here are the key news stories impacting Crescent Biopharma this week:

• Neutral Sentiment: CEO Joshua Brumm, COO Jonathan McNeill, CFO Richard Scalzo, and other insiders collectively sold 16,726 shares worth approximately $285,501 between September 16 and September 18. The sales reduced individual holdings by roughly 0.5% to 3.2%, but insiders continued to retain meaningful positions. SEC insider transaction filing
• Neutral Sentiment: All reported transactions were executed under pre-arranged Rule 10b5-1 trading plans and were described as sales to cover tax-withholding obligations tied to vested equity awards. That reduces the likelihood that the transactions represent a change in management’s outlook, although the aggregate selling may still weigh modestly on sentiment. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by senior executives—including the CEO and COO—could be viewed as a near-term supply or sentiment overhang. However, the relatively small percentage reductions and tax-related rationale make this a limited negative signal rather than a clear indication of weakening business prospects. SEC insider transaction filing

Crescent Biopharma Company Profile

Crescent Biopharma, Inc (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates.

Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources.

The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships.